8RK.F LABIANA HEALTH S.A.EO-10

Healthcare Pharmaceuticals Frankfurt Exchange
4.74 EUR
Close of Nov 11, 2026
4.12 7.70
Market cap
EUR 40.2M
P/E
13.5x
P/B
7.98x
ROE
50.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 8RK.F undervalued?

Graham number
Price4.74
Graham value2.16
Premium119.2%

8RK.F trades 119.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LABIANA HEALTH S.A.EO-10 fundamental analysis

No fundamental analysis for LABIANA HEALTH S.A.EO-10 yet.

LABIANA HEALTH S.A.EO-10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LABIANA HEALTH S.A.EO-10

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina La…

Full company profile